|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.60 EUR | -1.29% |
|
-4.32% | -26.19% |
| 05-15 | Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director | CI |
| 05-12 | Collegium completes acquisition of Azstarys® from Corium Therapeutics | RE |
| Market Cap | 1.13B 992M 920M 846M 1.6B 108B 1.63B 10.97B 4.29B 53.05B 4.24B 4.15B 183B | P/E 2026 * |
13.1x | P/E 2027 * | 9.34x |
|---|---|---|---|---|---|
| Enterprise Value | 1.88B 1.65B 1.53B 1.41B 2.66B 180B 2.72B 18.26B 7.14B 88.32B 7.06B 6.91B 305B | EV / Sales 2026 * |
2.15x | EV / Sales 2027 * | 1.64x |
| Free-Float |
77.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Collegium Pharmaceutical, Inc.
| 1 week | -4.32% | ||
| Current month | -1.90% | ||
| 1 month | +2.65% | ||
| 3 months | +3.02% | ||
| 6 months | -20.92% | ||
| Current year | -26.19% |
| 1 week | 30.4 |  | 33.2 |
| 1 month | 28.6 | | 33.2 |
| 3 years | 18.9 | | 42.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Vikram Karnani
CEO | Chief Executive Officer | 51 | 12/11/2024 |
Colleen Tupper
DFI | Director of Finance/CFO | 50 | 24/05/2021 |
Thomas Smith
CTO | Chief Tech/Sci/R&D Officer | 65 | 23/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Gino Santini
CHM | Chairman | 69 | 15/05/2025 |
John Freund
BRD | Director/Board Member | 72 | 01/02/2014 |
Garen Bohlin
BRD | Director/Board Member | 78 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29% | -4.32% | +9.15% | +58.97% | 1.14B | |
| -0.56% | -2.64% | +49.04% | +168.24% | 1,060B | |
| +0.31% | -2.00% | +64.29% | +63.06% | 619B | |
| -0.03% | -5.01% | +28.86% | +83.73% | 438B | |
| -1.75% | -2.91% | +28.78% | +24.35% | 333B | |
| +0.24% | -2.61% | +29.46% | +46.50% | 282B | |
| -1.75% | -12.77% | +20.67% | +23.05% | 267B | |
| +0.67% | -0.76% | -26.10% | -37.25% | 218B | |
| -0.81% | -3.66% | +22.07% | +59.72% | 196B | |
| +1.21% | +0.10% | +19.85% | +72.03% | 161B | |
| Average | -0.14% | -3.33% | +24.61% | +56.24% | 397.1B | |
| Weighted average by Cap. | +0.03% | -3.10% | +36.26% | +82.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 875M 768M 712M 655M 1.24B 83.63B 1.26B 8.49B 3.32B 41.08B 3.28B 3.21B 142B | 886M 778M 722M 664M 1.25B 84.71B 1.28B 8.6B 3.37B 41.61B 3.33B 3.25B 144B |
| Net income | 108M 95.08M 88.16M 81.07M 153M 10.35B 156M 1.05B 411M 5.08B 406M 397M 17.58B | 158M 139M 129M 119M 224M 15.14B 229M 1.54B 601M 7.44B 594M 581M 25.71B |
| Net Debt | 751M 660M 612M 562M 1.06B 71.8B 1.09B 7.29B 2.85B 35.27B 2.82B 2.76B 122B | 328M 288M 267M 245M 464M 31.33B 474M 3.18B 1.24B 15.39B 1.23B 1.2B 53.22B |
| Date | Price | Change |
|---|---|---|
| 13/07/26 | €30.60 | -1.29% |
| 10/07/26 | €31.00 | -0.64% |
| 09/07/26 | €31.20 | -0.64% |
| 08/07/26 | €31.40 | -2.48% |
| 07/07/26 | €32.20 | -2.42% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- COLL Stock
- 354 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
